PDLI Share Price

Open 2.22 Change Price %
High 2.32 1 Day 0.04 1.82
Low 2.21 1 Week 0.14 6.67
Close 2.24 1 Month -1.22 -35.26
Volume 2808769 1 Year -1.50 -40.11
52 Week High 3.95
52 Week Low 0.00
PDLI Important Levels
Resistance 2 2.34
Resistance 1 2.30
Pivot 2.26
Support 1 2.18
Support 2 2.14
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

PDL BioPharma, Inc. (NASDAQ: PDLI)

PDLI Technical Analysis 5
As on 9th Dec 2016 PDLI Share Price closed @ 2.24 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.16 & Strong Sell for SHORT-TERM with Stoploss of 3.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
PDLI Target for December
1st Target up-side 3.08
2nd Target up-side 3.7
3rd Target up-side 4.32
1st Target down-side 1.3
2nd Target down-side 0.68
3rd Target down-side 0.06
PDLI Other Details
Segment EQ
Market Capital 1108255104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.pdl.com
PDLI Address
PDLI
932 Southwood Boulevard
Incline Village, NV 89451
United States
Phone: 775-832-8500
Fax: 775-832-8501
PDLI Latest News
Interactive Technical Analysis Chart PDL BioPharma, Inc. ( PDLI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on PDL BioPharma, Inc.
PDLI Business Profile
PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.